Cerebrolysin: What It Is and Its U.S. Regulatory Status

What is Cerebrolysin?

Cerebrolysin is not a single peptide. It is a mixture of low-molecular-weight peptides and amino acids produced from purified proteins taken from pig (porcine) brain tissue. It is made by a pharmaceutical company in Austria.

Cerebrolysin has been studied in clinical trials, including trials in people recovering from stroke. It is approved for medical use in some countries outside the United States.

U.S. regulatory status

Current status: Not FDA-approved.

In practical terms, Cerebrolysin has not gone through the FDA review that a drug must pass before it can be marketed for use in people. There is no FDA-approved product that contains it.

Approval in another country does not make a drug approved in the United States. Each product must go through its own FDA review.

Why Peptide Labs does not sell Cerebrolysin

Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.

Anyone with questions about Cerebrolysin should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.

Related reading

See the full list of compound profiles in the Peptide Guide.